EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study

Antonella Poloni, Klas Raaschou-Jensen, Francisca Hernandez Mohedo, Stefania Paolini, Esther Natalie Oliva, Francesco Buccisano, Alberto Vasconcelos, Iris Kim, Aidan Makwana, David Bernasconi, Barbara Rosettani, Thomas Prebet und 1 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2024.10.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Antonella Poloni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Clinic, Azienda Ospedaliera Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy. Electronic address: a.poloni@u…. Hauptthemen laut MEDLINE: Lenalidomide, Myelodysplastic Syndromes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This noninterventional postauthorization safety study assessed the safety and effectiveness of lenalidomide in patients with transfusion-dependent, International Prognostic Scoring System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) associated with isolated deletion of 5q (del[5q]) who were treated in routine care. PATIENTS AND METHODS: Eligible adult patients in the lenalidomide cohort had transfusion-dependent, IPSS Low- or Int-1-risk MDS and isolated del(5q) and had received ≥ 1 dose of lenalidomide between 2014 and 2022. The primary endpoint was the 24-month cumulative incidence of acute myeloid leukemia (AML) progression. Overall survival (OS) was estimated by Kaplan-Meier analysis and safety data were collected. RESULTS: In total, 296 patients received ≥ 1 dose of lenalidomide (lenalidomide cohort, safety population) and 277 had received ≥ 1 complete cycle of lenalidomide (primary population). In the safety population, 44.3% of patients completed 3-year follow-up and 55.1% discontinued, with 33.1% discontinuing due to death. In the primary population, 24-month cumulative incidence of AML progression was 12.7% (95% confidence interval, 8.9%-17.1%) and estimated OS probability was 78.3% at 24 months and 63.9% at 36 months. Grade 3/4 treatment-emergent adverse events were experienced by 67.2% of the safety population, and these led to discontinuation in 35.5% of patients. There were no new safety signals. CONCLUSION: These real-world data support the established benefit-risk profile of lenalidomide in transfusion-dependent IPSS Low- or Int-1-risk MDS with isolated del(5q).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideMyelodysplastic SyndromesHumansMaleFemaleAgedMiddle AgedChromosome DeletionAged, 80 and overChromosomes, Human, Pair 5AdultBlood TransfusionEuropePrognosisProduct Surveillance, Postmarketing

Stichwörter der Autor:innen

Acute myeloid leukemiaDeletion 5qimmunomodulatory imide drugnoninterventional studyoverall survival

Substanzen

Lenalidomide

Autor:innen und Institutionen

  • Hematology Clinic, Azienda Ospedaliera Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy. Electronic address: a.poloni@univpm.it.
  • Department of Haematology, Odense University Hospital, Odense, Denmark.
  • Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA); Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Poloni, A., Raaschou-Jensen, K., Mohedo, F. H., Paolini, S., Oliva, E. N., Buccisano, F., Vasconcelos, A., Kim, I., Makwana, A., Bernasconi, D., Rosettani, B., Prebet, T., & Santini, V. (2025). Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.10.007

Vancouver

Poloni A, Raaschou-Jensen K, Mohedo FH, Paolini S, Oliva EN, Buccisano F, et al. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.10.007

BibTeX
@article{Poloni2025,
  author = {Poloni, Antonella and Raaschou-Jensen, Klas and Mohedo, Francisca Hernandez and Paolini, Stefania and Oliva, Esther Natalie and Buccisano, Francesco and Vasconcelos, Alberto and Kim, Iris and Makwana, Aidan and Bernasconi, David and Rosettani, Barbara and Prebet, Thomas and Santini, Valeria},
  title = {Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2024.10.007}
}
Kostenlos starten →